These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38486814)

  • 1. Combination of Extended Antivirals With Antiretrovirals for Severe Mpox in Advanced Human Immunodeficiency Virus Infection: Case Series of 4 Patients.
    Duong MT; Tebas P; Ancha B; Baron J; Chary P; Isaacs SN; Szep Z
    Open Forum Infect Dis; 2024 Mar; 11(3):ofae110. PubMed ID: 38486814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.
    Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City.
    Garcia EA; Foote MMK; McPherson TD; Lash MK; Bosompem AN; Bouscaren A; Chan J; DiLorenzo MA; Feihel D; Fowler RC; Gandhi V; Jenny-Avital ER; Kopping EJ; Mazo D; McLean J; Mgbako O; Sayegh MN; Shaw RN; Su M; Meissner JS; Wang JC; Wen W; Winters JC; Zeana CB; Zucker J; Wong M
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae294. PubMed ID: 38868307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in Managing Treatment-Resistant Mpox Complicated by Severe Superinfection.
    Fortier JC; Marsalisi C; Cordova E; Guo HJ; Verdecia J
    Open Forum Infect Dis; 2024 Apr; 11(4):ofae138. PubMed ID: 38651138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System.
    Vo C; Zomorodi R; Silvera R; Bartram L; Lugo LA; Kojic E; Urbina A; Aberg J; Sigel K; Chasan R; Patel G
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad552. PubMed ID: 38023539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review.
    Bruno G; Buccoliero GB
    Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis.
    Shamim MA; Satapathy P; Padhi BK; Veeramachaneni SD; Akhtar N; Pradhan A; Agrawal A; Dwivedi P; Mohanty A; Pradhan KB; Kabir R; Rabaan AA; Alotaibi J; Al Ismail ZA; Alsoliabi ZA; Al Fraij A; Sah R; Rodriguez-Morales AJ
    Front Pharmacol; 2023; 14():1149909. PubMed ID: 37214444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antivirals With Activity Against Mpox: A Clinically Oriented Review.
    Siegrist EA; Sassine J
    Clin Infect Dis; 2023 Jan; 76(1):155-164. PubMed ID: 35904001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing of the antibiotic nitroxoline for the treatment of mpox.
    Bojkova D; Zöller N; Tietgen M; Steinhorst K; Bechtel M; Rothenburger T; Kandler JD; Schneider J; Corman VM; Ciesek S; Rabenau HF; Wass MN; Kippenberger S; Göttig S; Michaelis M; Cinatl J
    J Med Virol; 2023 Mar; 95(3):e28652. PubMed ID: 36897017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging pharmacological strategies for treating and preventing mpox.
    Grosenbach DW; Russo AT; Blum ED; Hruby DE
    Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of tecovirimat in subjects with Mpox.
    Tempestilli M; Mondi A; D'Avolio A; Forini O; Pinnetti C; Mazzotta V; Gagliardini R; Beccacece A; De Nicolò A; Faccendini P; Cimini E; Maggi F; Girardi E; Nicastri E; Boffito M; Vaia F; Antinori A
    Int J Antimicrob Agents; 2024 Feb; 63(2):107068. PubMed ID: 38141836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal Case of Progressive Mpox in a Patient with AIDS-Viral Enteropathy and Malabsorption Demanding the Use of Full Parenteral ARV and Endovenous Cidofovir.
    Caria J; Vara-Luiz F; Maia I; Joosten A; Val-Flores L; Pinheiro H; Póvoas D; Germano N; Maltez F
    Infect Dis Rep; 2023 Mar; 15(2):171-179. PubMed ID: 36960970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat.
    Brown L; Sargent P; Islam M; Downie C; Hassan A; O'Hara G; Douthwaite S; Kulasegaram R; Robbie S; Aarons E; Milligan ID
    HIV Med; 2024 Sep; 25(9):1086-1090. PubMed ID: 38725328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mpox in people with advanced HIV infection: a global case series.
    Mitjà O; Alemany A; Marks M; Lezama Mora JI; Rodríguez-Aldama JC; Torres Silva MS; Corral Herrera EA; Crabtree-Ramirez B; Blanco JL; Girometti N; Mazzotta V; Hazra A; Silva M; Montenegro-Idrogo JJ; Gebo K; Ghosn J; Peña Vázquez MF; Matos Prado E; Unigwe U; Villar-García J; Wald-Dickler N; Zucker J; Paredes R; Calmy A; Waters L; Galvan-Casas C; Walmsley S; Orkin CM;
    Lancet; 2023 Mar; 401(10380):939-949. PubMed ID: 36828001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection.
    Stafford A; Rimmer S; Gilchrist M; Sun K; Davies EP; Waddington CS; Chiu C; Armstrong-James D; Swaine T; Davies F; Gómez CHM; Kumar V; ElHaddad A; Awad Z; Smart C; Mora-Peris B; Muir D; Randell P; Peters J; Chand M; Warrell CE; Rampling T; Cooke G; Dhanji S; Campbell V; Davies C; Osman S; Abbara A
    Lancet Infect Dis; 2023 Jun; 23(6):e218-e226. PubMed ID: 36773621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mpox in the New York metropolitan area, Summer 2022.
    Gnanaprakasam R; Keller M; Glassman R; El-Khoury MY; Chen DS; Feola N; Feldman J; Chaturvedi V
    J Med Virol; 2023 Apr; 95(4):e28699. PubMed ID: 36951318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tecovirimat for the treatment of severe Mpox in Germany.
    Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S
    Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antivirals for the treatment of Monkeypox: utilization in the general and HIV-positive population and gaps for research. A short narrative review.
    Ivanov DT; Slabakova YA; Argirova RM; Valkov TK
    Infez Med; 2023; 31(2):186-194. PubMed ID: 37283638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mpox Recurrence and Tecovirimat Resistance in a Patient With Advanced Human Immunodeficiency Virus Disease.
    Griffith DC; Fall A; Carter M; Traut CC; Sop J; Hansoti B; Gebo KA; Mostafa HH; Blankson JN
    Open Forum Infect Dis; 2024 Oct; 11(10):ofae549. PubMed ID: 39371365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mpox in people with past infection or a complete vaccination course: a global case series.
    Hazra A; Zucker J; Bell E; Flores J; Gordon L; Mitjà O; Suñer C; Lemaignen A; Jamard S; Nozza S; Nori AV; Pérez-Barragán E; Rodríguez-Aldama JC; Blanco JL; Delaugerre C; Turner D; Fuertes I; Leiro V; Walmsley SL; Orkin CM;
    Lancet Infect Dis; 2024 Jan; 24(1):57-64. PubMed ID: 37678309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.